A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry

被引:35
作者
Ansari, Marc [2 ]
Uppugunduri, Chakradhara Rao S. [2 ]
Deglon, Julien [3 ]
Theoret, Yves [4 ]
Versace, Francois [3 ]
Gumy-Pause, Fabienne [2 ]
Ozsahin, Hulya [2 ]
Dayer, Pierre [1 ]
Desmules, Jules [1 ]
Daali, Youssef [1 ]
机构
[1] Univ Hosp Geneva, Clin Pharmacol & Toxicol Serv, CH-1211 Geneva 14, Switzerland
[2] Univ Hosp Geneva, Oncohematol Unit, Dept Pediat, CH-1211 Geneva 14, Switzerland
[3] Univ Ctr Legal Med, Toxicol Unit, Geneva, Switzerland
[4] Univ Montreal, Dept Pharmacol, CHU St Justine, Montreal, PQ H3C 3J7, Canada
关键词
STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; CHRONIC MYELOID-LEUKEMIA; TOTAL-BODY IRRADIATION; INTRAVENOUS BUSULFAN; PEDIATRIC-PATIENTS; GRAFT-REJECTION; HUMAN PLASMA; LC-MS/MS; QUANTIFICATION;
D O I
10.1002/rcm.6241
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
RATIONALE Busulfan (Bu) is an important component of the myeloablative conditioning regimen prior to hematopoietic stem cell transplantation (HSCT) especially in children. Intravenously administered Bu exhibits a therapeutic window phenomenon requiring therapeutic drug monitoring. Analytical methods developed for Bu routine monitoring were aimed at using low volumes of biological fluids and development of simple procedures to facilitate the dosage adjustment. In this report, we describe a simple, rapid method for Bu measurement using dried blood spots (DBS) from only 5 mu L of whole blood. METHODS Bu extracted from DBS with methanol was measured by high-performance liquid chromatography with electrospray ionization and tandem mass spectrometry in multiple reaction monitoring mode using D8-Bu as an internal standard. The method was in-house validated evaluating trueness, repeatability, within-laboratory reproducibility, specificity and the lower limit of quantification (LLOQ). RESULTS The method was linear in the calibration range of 1002000?ng?mL1 (r2 >0.99) encompassing the therapeutic concentrations of Bu. A good trueness (<14%), precision (<10%), and recovery (100%) were observed during validation of the method with quality controls of 300, 600 and 1400?ng?mL1. The LLOQ was determined as 50?ng?mL1 and no matrix or carryover effects were observed. The validated method was applied to measure Bu levels in four children receiving infusion of Bu prior to HSCT. A good correlation was observed between the Bu levels measured by DBS and dried plasma spot (DPS) (r2?=?0.96) and between DPS and the GC/MS method (r2?=?0.92). Bu was found to be stable in DBS up to 6?h at room temperature and for 24?h at 4 degrees C. CONCLUSIONS The new DBS method facilitates earlier dosage adjustment during Bu therapy by its specific and simple procedure using 5 mu L of whole blood. Copyright (C) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:1437 / 1446
页数:10
相关论文
共 59 条
[11]   Determination of Busulfan in Human Plasma Using an ELISA Format [J].
Courtney, Jodi B. ;
Harney, Rebecca ;
Li, Yunying ;
Lundell, Gregory ;
McMillin, Gwendolyn A. ;
Agarwal, Geeta ;
Juenke, JoEtta M. ;
Mathew, Anu ;
Gonzalez-Espinoza, Rita ;
Fleisher, Martin ;
Salamone, Salvatore J. .
THERAPEUTIC DRUG MONITORING, 2009, 31 (04) :489-494
[12]   Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results [J].
Dalle, JH ;
Wall, D ;
Theoret, Y ;
Duval, M ;
Shaw, L ;
Larocque, D ;
Taylor, C ;
Gardiner, J ;
Vachon, MF ;
Champagne, MA .
BONE MARROW TRANSPLANTATION, 2003, 32 (07) :647-651
[13]   Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite [J].
Deglon, Julien ;
Thomas, Aurelien ;
Daali, Youssef ;
Lauer, Estelle ;
Samer, Caroline ;
Desmeules, Jules ;
Dayer, Pierre ;
Mangin, Patrice ;
Staub, Christian .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2011, 54 (02) :359-367
[14]   ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA IN FIRST CHRONIC PHASE - A RANDOMIZED TRIAL OF BUSULFAN-CYTOXAN VERSUS CYTOXAN-TOTAL-BODY IRRADIATION AS PREPARATIVE REGIMEN - A REPORT FROM THE FRENCH-SOCIETY-OF-BONE-MARROW-GRAFT (SFGM) [J].
DEVERGIE, A ;
BLAISE, D ;
ATTAL, M ;
TIGAUD, JD ;
JOUET, JP ;
VERNANT, JP ;
BORDIGONI, P ;
IFRAH, N ;
DAURIAC, C ;
CAHN, JY ;
LIOURE, B ;
TROUSSARD, X ;
REIFFERS, J ;
GRATECOS, N ;
MILPIED, N ;
BELANGER, C ;
GUYOTAT, D ;
TILLY, H ;
MICHALLET, M ;
GLUCKMAN, E .
BLOOD, 1995, 85 (08) :2263-2268
[15]   Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry [J].
dos Reis, EO ;
Vianna-Jorge, R ;
Suarez-Kurtz, G ;
Lima, ELD ;
Azevedo, DD .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2005, 19 (12) :1666-1674
[16]   Dried Blood Spot Methods in Therapeutic Drug Monitoring: Methods, Assays, and Pitfalls [J].
Edelbroek, Peter M. ;
van der Heijden, Jacques ;
Stolk, Leo M. L. .
THERAPEUTIC DRUG MONITORING, 2009, 31 (03) :327-336
[17]   BINDING OF BUSULFAN TO PLASMA-PROTEINS AND BLOOD-CELLS [J].
EHRSSON, H ;
HASSAN, M .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1984, 36 (10) :694-696
[18]   GAS-CHROMATOGRAPHIC ANALYSIS OF BUSULFAN FOR THERAPEUTIC DRUG-MONITORING [J].
EMBREE, L ;
BURNS, RB ;
HEGGIE, JR ;
PHILLIPS, GL ;
REECE, DE ;
SPINELLI, JJ ;
HARTLEY, DO ;
HUDON, NJ ;
GOLDIE, JH .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 32 (02) :137-142
[19]   Stability of Acylcarnitines and Free Carnitine in Dried Blood Samples: Implications for Retrospective Diagnosis of Inborn Errors of Metabolism and Neonatal Screening for Carnitine Transporter Deficiency [J].
Fingerhut, Ralph ;
Ensenauer, Regina ;
Roechinger, Wulf ;
Arnecke, Ralf ;
Olgemoeller, Bernhard ;
Roscher, Adelbert A. .
ANALYTICAL CHEMISTRY, 2009, 81 (09) :3571-3575
[20]   Use of saliva and capillary blood samples as substitutes for venous blood sampling in pharmacokinetic investigations of artemisinin [J].
Gordi, T ;
Hai, TN ;
Hoai, NM ;
Thyberg, M ;
Ashton, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (08) :561-566